Author:
Gerding Heinrich,Loukopoulos Vlassios,Riese Juliane,Hefner Lars,Timmermann Melanie
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology
Reference24 articles.
1. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900–1901
2. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrenbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115:116–126
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age related macular degeneration. N Engl J Med 355:1419–1431
5. EMEA (2007) Lucentis: Summary of product characteristics. www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/emea-comined-h715en.pdf . Accessed: July, 20th, 2010